A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
暂无分享,去创建一个
Huyuan Yang | A. Hui | D. Seldin | A. Dispenzieri | V. Kukreti | G. Merlini | S. Schönland | J. Zonder | G. Palladini | V. Sanchorawala | A. Jaccard | R. Comenzo | A. Cohen | N. Gupta | D. Berg
[1] A. Foli,et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. , 2017, Blood.
[2] K. Venkatakrishnan,et al. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling , 2017, Clinical Pharmacokinetics.
[3] G. Merlini,et al. What is new in diagnosis and management of light chain amyloidosis? , 2016, Blood.
[4] Huyuan Yang,et al. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment , 2016, British journal of clinical pharmacology.
[5] A. Palumbo,et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.
[6] P. Hari,et al. New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] A. Hui,et al. The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma , 2016, Journal of clinical pharmacology.
[8] D. Seldin,et al. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial. , 2007, Blood.
[9] D. Esseltine,et al. Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study , 2015, Journal of Hematology & Oncology.
[10] David D. Smith,et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis , 2015 .
[11] A. Foli,et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. , 2015, Blood.
[12] M. Dimopoulos,et al. Long‐term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies , 2015, American journal of hematology.
[13] D. Dingli,et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis , 2015, American journal of hematology.
[14] B. Barlogie,et al. Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib , 2015, Blood Cancer Journal.
[15] A. Wu,et al. Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients’ supportive care needs , 2015, Quality of Life Research.
[16] Neeraj Gupta,et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. , 2014, The Lancet. Oncology.
[17] D. Esseltine,et al. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. , 2014, Blood.
[18] A. Foli,et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. , 2014, Blood.
[19] Michael L. Wang,et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. , 2014, Blood.
[20] A. Hui,et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. , 2014, Blood.
[21] A. Foli,et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach , 2014, Haematologica.
[22] G. Palladini,et al. Update on treatment of light chain amyloidosis , 2014, Haematologica.
[23] D. Seldin,et al. Immunoglobulin light chain amyloidosis , 2014, Expert review of hematology.
[24] G. Merlini,et al. Light chain amyloidosis: the heart of the problem , 2013, Haematologica.
[25] D. Seldin,et al. New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] G. Merlini,et al. Systemic light chain amyloidosis: an update for treating physicians. , 2013, Blood.
[27] M. Dimopoulos,et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] P. L. Bergsagel,et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. , 2012, Blood.
[29] D. Dingli,et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Esseltine,et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. , 2011, Blood.
[31] S. Levene,et al. Functional 20S proteasomes in mature human red blood cells , 2011, Experimental biology and medicine.
[32] D. Seldin,et al. Amyloidosis: pathogenesis and new therapeutic options. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R. Comenzo,et al. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. , 2010, Hematology. American Society of Hematology. Education Program.
[34] M. Rolfe,et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.
[35] A. Dispenzieri,et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. , 2008, Blood.
[36] A. Dispenzieri,et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response , 2007, Haematologica.
[37] G. Merlini,et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. , 2007, Blood.
[38] R. Comenzo. Managing systemic light-chain amyloidosis. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.
[39] A. Dispenzieri,et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. , 2007, Blood.
[40] M. Skinner,et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. , 2007, Blood.
[41] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[42] P. Elliott,et al. Proteasome inhibition measurements: clinical application. , 2000, Clinical chemistry.
[43] R. Kyle,et al. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.